Delivery Order SPE2DB22D3401-SPE2DB25FT3HX
- Not listed
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for Ondansetron ODT 4 mg tablets (30-count) valued at $4,536.73 under a firm fixed-price contract type. The award was made on August 22, 2025, with an ultimate completion date of August 25, 2025. This is a non-set-aside award, indicating it was competitively awarded. The place of performance is located at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- AmerisourceBergen Drug Corp was awarded a delivery order on August 1, 2025, by the Defense Logistics Agency's Medical Supply Chain to provide Ondansetron ODT 4 mg tablets (30-count) with a firm fixed price ceiling value of $5,173.92. The order is scheduled for completion by August 4, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This non-set-aside award represents a routine pharmaceutical procurement supporting federal medical supply needs, consistent with...
- AmerisourceBergen Drug Corp was awarded a delivery order on July 30, 2025, by the Defense Logistics Agency's Medical Supply Chain to supply Ondansetron ODT 8 mg tablets in a 30-count quantity. This is a non-set-aside, competitively awarded firm fixed price delivery order with a ceiling value of $1,438.73 and an ultimate completion date of July 31, 2025. The place of performance is the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $1,793.24 by the Defense Logistics Agency (DLA) on September 9, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. The contract is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and was competitively awarded with no set-aside designation. This award is issued under...
- AmerisourceBergen Drug Corp received a competitively awarded delivery order from the Defense Logistics Agency's Medical Supply Chain for Ondansetron ODT 4 mg tablets (30-count units) valued at $31,190.34. The contract was awarded on September 18, 2025, with an ultimate completion date of September 19, 2025, and carries firm fixed pricing with no set-aside designation. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this delivery order,...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a delivery order award from the Defense Logistics Agency (DLA) on August 19, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $21,254.05 and an ultimate completion date of August 20, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. As a major pharmaceutical distributor...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 15, 2025, for the supply of Ondansetron ODT 4 mg tablets in a 30-count package. This is a firm fixed-price delivery order with a ceiling value of $1,616.85 and an ultimate completion date of September 16, 2025. The award was made on a competitive, non-set-aside basis, and performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is...
- AmerisourceBergen Drug Corp was awarded a delivery order on September 18, 2025, valued at $5,824.12 for the supply of Ondansetron ODT 8 mg tablets in quantities of 30s under a firm fixed price contract. This is a non-set-aside award issued by the Defense Logistics Agency's Medical Supply Chain, with an ultimate completion date of September 19, 2025. The work will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $26,868.47 by the Defense Logistics Agency (DLA) on July 14, 2025, for the supply of Ondansetron HCL 4 mg tablets in quantities of 30. The contract carries a firm fixed price structure with no set-aside designation, indicating competitive award status. Performance is based in Conshohocken, Pennsylvania, with an ultimate completion date of July 15, 2025. This delivery order represents a child contract issued under...
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on September 12, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $14,942.02 and an ultimate completion date of September 15, 2025. The contract is unclassified as a set-aside and represents a competitive award to AmerisourceBergen, a major pharmaceutical distributor based in Conshohocken,...
- SPE2DB22D3401Indefinite Delivery Contract
- SPE2DB22D3401-SPE2DB25FT3HXDelivery Order
AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on April 24, 2025, for the supply of Ondansetron ODT 4 mg tablets in a 30-count package. This contract, valued at $20,565.05, represents a firm fixed-price delivery order with an ultimate completion date of April 25, 2025. The award was made on a competitive basis without any set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania—which serves as the place of performance—is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This comprehensive pharmaceutical support vehicle enables the contractor to supply a broad range of medications, medical devices, and healthcare commodities to support military healthcare programs globally. The company's federal contract portfolio demonstrates extensive experience fulfilling diverse pharmaceutical needs across multiple therapeutic domains, positioning it as a key vendor for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.6k | 4/24/25 |